Kemadrin

Procyclidine Hydrochloride, the active ingredient in Kemadrin, is an anticholinergic (muscarinic antagonist) presented as a tablet for oral use. It is employed to manage Parkinson's disease and drug‑induced extrapyramidal symptoms in adult patients, helping restore the dopamine‑acetylcholine balance in the central nervous system.

GNH USA supplies Kemadrin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides regulatory‑approved batches for global distribution.

Kemadrin (procyclidine) is used in the management of movement disorders that involve cholinergic overactivity.

- Parkinson's disease: improves motor control, reduces tremor and rigidity. - Drug‑induced extrapyramidal symptoms: alleviates rigidity, dystonia and akathisia caused by antipsychotic therapy. - Parkinsonian tremor: diminishes tremor intensity and enhances daily functioning.

Procyclidine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Dry mouth - Constipation - Blurred vision - Dizziness

Serious or Rare Side Effects: - Confusion or delirium - Hallucinations - Severe tachycardia - Allergic reactions such as rash or angioedema

When prescribing Kemadrin, clinicians should consider several safety measures to minimize risk.

- Assess renal function: adjust use in severe renal impairment. - Monitor cognitive status: elderly patients may develop confusion or memory problems. - Avoid in glaucoma: anticholinergic effect can increase intra‑ocular pressure. - Use caution with other anticholinergics: additive effects may exacerbate dryness and constipation. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Procyclidine can interact with other medicines, requiring attention to avoid additive or antagonistic effects.

Major Interactions (Avoid): - Antihistamines (e.g., diphenhydramine): additive anticholinergic burden. - Tricyclic antidepressants: increased risk of anticholinergic toxicity. - Antipsychotics (e.g., haloperidol): may worsen extrapyramidal symptoms. - Cholinesterase inhibitors (e.g., donepezil): pharmacodynamic antagonism reducing efficacy.

Moderate Interactions (Monitor Closely): - Beta‑blockers: potential for enhanced bradycardia. - Opioids: may increase sedation and respiratory depression. - Alcohol: can amplify dizziness and CNS depression.